Sign In
Buy CELZ
$0.86
-0.0160 (-1.82%)
At Close: Jul 20, 2026
PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology
Creative Medical Technology Holdings Provides Corporate Update
09:00am, Wednesday, 27'th Mar 2024
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approac
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
12:06pm, Thursday, 07'th Mar 2024
Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The com
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
07:00am, Wednesday, 06'th Mar 2024
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocri
Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial
08:57am, Thursday, 21'st Dec 2023
New York, December 21, 2023 – Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company's innovative StemSpine
PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical tri
Creative Medical Technology Holdings Provides Corporate Update
08:00am, Wednesday, 15'th Nov 2023
Continuing to Advance Regenerative Therapies for Diabetes and Chronic Lower Back Pain Strong Financial Position with No Long-Term Debt PHOENIX , Nov. 15, 2023 /PRNewswire/ -- Creative Medical Techno
Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX , Oct. 10, 2023 /P
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
01:31pm, Friday, 22'nd Sep 2023
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in t
PHOENIX , Sept. 19, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative a
What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?
10:45am, Thursday, 24'th Aug 2023
PHOENIX, AZ / ACCESSWIRE / August 24, 2023 / Biotechnology company Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) seems to be witnessing success in the allogeneic cell therapy market. In Q4
PHOENIX, AZ / ACCESSWIRE / July 14, 2023 / Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update
09:00am, Thursday, 13'th Jul 2023
PHOENIX, AZ / ACCESSWIRE / July 13, 2023 / Creative Medical Technology Holdings, Inc. ("Creative Medical Technology") (NASDAQ:CELZ) recently released an update on their drug pipeline and financial sta
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
01:39pm, Thursday, 13'th Apr 2023
Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.
